CYBN

Cybin Inc.
Healthcare — Biotechnology
Valhalla Score 65
A proprietary composite score from 0–100 measuring a stock's technical strength, sector-relative performance, and institutional flow activity. Higher scores indicate stronger setups.
$8.28

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

📊 Key Statistics

Market Cap$413M
P/E Ratio
EPS (TTM)
EPS YoY
Revenue YoY
Float
Short Float %
Inst. Ownership
Sector RS

📈 Fundamentals

ROE
ROIC
ROA
Current Ratio
Debt/Equity
Gross Margin
Net Margin
Dividend Yield
Next Earnings

Options Summary

Call OI
Put OI
P/C Ratio (OI)
Gamma Environment
Max Pain
Call Wall
Put Wall

🎯 Analyst Estimates

Consensus Target
High Target
Low Target
Analysts
Upside/Downside

📋 Quarterly Financials

Period Revenue Rev YoY EPS EPS YoY Gross Margin
Start Free Trial See full options flow, dark pool data & more

🔥 Recent Options Flow

TypeStrikeExpSizePremiumTime
Start Free Trial Institutional trades, dark pool vs lit exchange

🏛️ Institutional Trades

TypePriceSizeValueVenueTime
Start Free Trial Full insider & congressional trade history

👤 Insider Trades

NameTypeSharesPriceDate
Start Free Trial Top institutional holders & ownership data

🏦 Top Institutional Holders

InstitutionSharesValue% of Class

Start Your Free Trial

Have a referral code?

14-day free trial then $70/month. Cancel anytime.

Welcome to Valhalla